Synapse - Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)

Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd) Meeting Abstract

Authors:	Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Tan, C.; Hultcrantz, M.; Scordo, M.; Kazandjian, D.; Shah, G. L.; Landau, H. J.; Chung, D. J.; Giralt, S.; Bruno, B.; Zhang, Y.; Arbini, A. A.; Dogan, A.; Lesokhin, A.; Davies, F. E.; Korde, N.; Morgan, G. J.; Landgren, O.
Abstract Title:	Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
Meeting Title:	63rd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	138
Issue:	Suppl. 1
Meeting Dates:	2021 Dec 11-14
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2021-11-23
Language:	English
ACCESSION:	WOS:000736398801102
DOI:	10.1182/blood-2021-149112
PROVIDER:	wos
Notes:	Meeting Abstract: 325 -- Hybrid meeting, also took place online -- Source: Wos